Last updated on June 2020

Phase I/II Study of Avelumab in Pediatric Cancer Subjects

Brief description of study

This is a multi-center, open-label, international study to evaluate the dose, safety and tolerability, antitumor activity, pharmacokinetic and pharmacodynamics of avelumab in pediatric subjects 0 to less than 18 years of age with refractory or relapsed malignant solid tumors (including central nervous system tumors) and lymphoma for which no standard therapy is available or for which the subject is not eligible for the existing therapy.

Clinical Study Identifier: NCT03451825

Find a site near you

Start Over